ClinicalTrials.gg
CompletedNCT01927432Updated Feb 9, 2024

Ultrasound Characterization of Ovarian Follicle Dynamics in Women With Amenorrhea

An observational study in Oligomenorrhea, Amenorrhea and Polycystic Ovary Syndrome (PCOS), sponsored by Cornell University. Completed at 1 site in United States. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-09.

Sponsored by Cornell University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
73
Ages
18 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Amenorrhea with a site in United States — 7 open to participants now, 9 under way, 1 of them phase 3. Amenorrhea · United States.

Enrollment
10th of 13
73 · median 111
Started
2011
with 1 other
Observational
13 of 43
3 open now
Registered
23rd of 43
by date
Lead sponsor
3 of 43
Cornell University

Among the 43 studies in Amenorrhea with a site in United States, this one is the 10th largest by enrollment of the 13 observational ones that give a count, is one of 2 that started in 2011, is one of 13 observational ones, and was the 23rd registered.

Amenorrhea

80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.

Browse Amenorrhea studies →

Open to participants now

7 of the 43 studies in Amenorrhea with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Amenorrhea studies recruiting now, none (0%) set no upper age limit and 11 (85%) stop at 75 or younger; 8 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 35 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Amenorrhea with a site in United States, or all of them as a file.
02

Study summary

In women with regular menstrual cycles, antral follicles have been shown to grow in synchronous cohorts, called waves, 2-3 times in a menstrual cycle. It is unknown whether these waves of follicle growth also occur in women with amenorrhea or if there is abnormal/absent follicle growth. Further, oligo- or amenorrhea has been associated with metabolic disturbances, such as over- or under-nutrition, central obesity and insulin resistance. Yet, mechanisms whereby metabolic factors influence folliculogenesis in women are poorly understood. To understand potential mechanisms, the investigators plan to characterize follicle growth dynamics in women with or without regular menstrual cycles and identifying key metabolic differences in these women which may be important in normal follicle development and fertility.

Read the detailed description

In the ovaries, eggs rest in fluid filled sacs called follicles. When follicles grow they form small fluid-filled cysts that can be easily seen when we use ultrasound to view the ovaries. In women with regular menstrual cycles, groups of 10 to 20 follicles grow and regress at 2 or 3 different times during their cycle (usually over a 28- day period). Several of these follicles grow to a stage where they begin to develop the potential to ovulate - but in general only one follicle is chosen to ovulate. Thus, at any given time during the menstrual cycle, numerous fluid-filled follicles can be visualized in a woman's ovaries at various stages of development using transvaginal ultrasonography. In women with absent or infrequent menstrual cycles, very little is known about the growth patterns of their follicles and how factors such as metabolic hormones, might play a role in the failure to ovulate. Being underweight or overweight increases your chances of having irregular or absent menstrual cycles and that a history of abnormal reproductive function compounds a woman's risk for chronic diseases such as infertility, diabetes, hypertension, atherosclerosis and certain cancers. This is particularly the case for women with polycystic ovary syndrome (PCOS) that have menstrual cycles that appear to worsen or improve depending on their body weight and metabolic status. PCOS is an endocrine disorder that affects 6-12% of reproductive-aged women within the general population. The hallmark features of PCOS are menstrual irregularity, increased levels of androgens, and polycystic ovaries. The current diagnostic criteria require 2 out of 3 of these features to be present for the diagnosis, therefore a number of phenotypes of PCOS exist. However, the metabolic and reproductive differences across the phenotypic spectrum of PCOS are not well understood. Women with PCOS characteristically have polycystic ovaries, where up to 10 times more follicles are present in the ovary at any given time. Further, the follicle-size populations and overall distribution throughout the ovary varies in women - follicles may be situated around the periphery of the ovary or may be distributed throughout the ovary. Presumably these small follicles are arrested in development - but emerging data from the Lujan laboratory suggest that this is not the case. It is assumed that ovulation does not occur and that follicles do not grow in a normal wave pattern. In truth, no study has ever looked to see whether follicles are actually growing, regressing or are arrested in women with irregular/absent menstrual cycles. By comparing follicle wave dynamics, reproductive hormones and markers of metabolism in women with regular and irregular menstrual cycles, the researchers plan to identify what factors might explain why fertility potential and long-term health are compromised in some women but not in others. Further, we will determine if any of these metabolic factors are unique to PCOS representing specific metabolic risks or follicle growth impairment. The ultimate goal of this research is to understand how body composition, nutrition and metabolism regulate follicle development in women so we can better develop lifestyle and drug therapies to help women preserve their fertility and long-term health. Since obesity has recently become the leading cause of infertility in North America, these studies are especially important.

To accomplish our objective, the investigators plan to recruit up to 40 women with regular menstrual cycles and up to 40 women with irregular/absent menstrual cycles. Our goal is to recruit an equal number of women in each group such that they are matched for age (18 - 35 years old) and body mass index (BMI; Normal weight = 18 - 24 kg/m2; Overweight = 25 - 29 kg/m2; Obese = 30kg/m2). Women will undergo serial ultrasonographic of their ovaries every other day from ovulation to ovulation in women with regular menstrual cycles or for 5 weeks in women with cycle irregularity. Blood samples will be collected at each visit. Ultrasound scans of the ovaries will be assessed for the total number, size, and distribution of follicles using ultrasound imaging techniques. Blood samples collected will be assayed to determine serum concentrations of luteinizing hormone (LH), follicle stimulating hormone (FSH), estradiol, progesterone, anti-müllerian hormone (AMH), and inhibin B. During day 3-5 in women with regular menstrual cycles or at a time where no dominant follicle or corpus luteum is present, an early morning visit will be conducted to assess the following metabolic parameters : (1) 75-gram oral glucose tolerance test to characterize glucose and insulin dynamics at 0, 30, 60, 90, and 120 minutes post-glucose ingestion; (2) dual X-ray absorptiometry (DXA) scan to quantify body fat and lean muscle distribution; (3) vitals and anthropometry assessment to measure waist and hip circumference, height, weight, blood pressure, and heart rate, and (4) fasting blood tests to detect serum concentrations of androgens (i.e., total testosterone, androstenedione, free androgen index) and serum markers of metabolic syndrome (i.e., lipids and hemoglobin A1C); (5) optional subcutaneous fat biopsy to analyze fat cells, which represent a site of reproductive hormone synthesis.

03

Conditions studied

  • Oligomenorrhea
  • Amenorrhea
  • Polycystic Ovary Syndrome (PCOS)

Keywords

  • Polycystic Ovary Syndrome (PCOS)
  • Nutrition
  • Metabolism
  • Antral follicle growth
  • Menstrual Cyclicity
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Women must be able to transport to Cornell University in Ithaca, NY. Eligible participants are between 18-35 years with a BMI of 18 kg/m2 or higher. Women are screened and enrolled following consent based on their response to our advertisements. Enrollment is restricted to the geographical area.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 18 and 35 years
  • ≥ 18 kg/m2
  • If ≥ 21 years old, must have had healthy pelvic exam w/in past 2 years

Either:

  • Regular menstrual cycles (21-35 days);
  • Irregular menstrual cycles (>36 days) with or without a previous diagnosis of PCOS from a primary care provider

Exclusion criteria

Exclusion Criteria:

  • Current use of medication(s) known or suspected to interfere with reproductive function (eg. oral ) or insulin sensitivity
  • Pregnant or breastfeeding
  • Not otherwise healthy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
73 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Regular menstrual cycles

    Adult women will be assigned to this category if they report a history of regular menstrual cycles.

  • Irregular menstrual cycles

    Adult women will be assigned to this category if they report a history of irregular menstrual cycles, including women with a pre-existing diagnosis of PCOS.

06

What researchers measure

Primary outcomes

  1. Follicle number

    The number of all antral follicles in each ovary will be determined using ultrasonography for each participant. Changes in follicle number over time will be compared between groups.

    Time frame: 4-5 weeks

  2. Follicle diameter

    The diameter of all follicles \>2mm will be determined using ultrasonography for each participant. Changes in follicle diameter over time will be compared between groups.

    Time frame: 4-5 weeks

Secondary outcomes

  1. Ovarian Volume

    The size of each ovary will be determined using ultrasonography for each participant during study participation and compared between groups.

    Time frame: 4-5 weeks

  2. Anti-Müllerian hormone

    The serum AMH concentration will be determined during study participation and assessed in association with the change in follicle number, diameter and between groups.

    Time frame: 4-5 weeks

  3. Serum FSH concentration

    The serum FSH concentration will be determined during study participation and assessed in association with the change in follicle number, diameter and between groups.

    Time frame: 4-5 weeks

  4. Serum LH concentration

    The serum FSH concentration will be determined during study participation and assessed in association with the change in follicle number, diameter and between groups.

    Time frame: 4-5 weeks

  5. Serum progesterone concentration

    The serum progesterone concentration will be determined during study participation, assessed in association with luteal dynamics and compared between groups.

    Time frame: 4-5 weeks

  6. LH-FSH ratio

    The ratio of circulating LH to FSH concentrations will be determined for each participant and compared between groups.

    Time frame: 4-5 weeks

  7. Insulin sensitivity

    Insulin sensitivity will be determined by administration of an oral glucose tolerance test and compared between groups.

    Time frame: 1 day

  8. Androgen concentrations

    Total testosterone, androstenedione and free androgen index concentrations in serum will be determined and compared between groups.

    Time frame: 1 day

  9. Menstrual Cycle Length

    Average menstrual cycle length as determined by self-reported history and the menstrual cycle length during study participation will be determined and compared between groups.

    Time frame: 4-5 weeks

  10. Hirsutism

    Degree of hirsutism as judged by the Ferriman-Gallwey scale will be determined and compared between groups.

    Time frame: 1 day

  11. Serum markers of metabolic syndrome

    Lipids, glucose and HbA1C concentrations will be determined and compared between groups.

    Time frame: 1 day

  12. Blood Pressure

    Blood pressure will be determined and compared between groups.

    Time frame: 1 day

  13. Body mass index

    The ratio of weight to height will be determined and compared between groups.

    Time frame: 1 day

  14. Waist-to-hip ratio

    The ratio of waist circumference to hip circumference will be determined and compared between groups.

    Time frame: 1 day

  15. Body fat distribution

    Percentage and distribution of fat and lean mass as assessed using DXA technology will be compared between groups.

    Time frame: 1 day

  16. Subcutaneous fat biopsy (optional)

    Fat cells, representing an important site of reproductive hormone production, will be compared between groups.

    Time frame: 1 day

07

Study locations

1 site
  • Human Metabolic Research Unit, Cornell University
    Ithaca, New York 14853, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Sep 2021 and a completion of Sep 2021. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2013
First posted
Aug 22, 2013
Start
Sep 2011
Primary completionActual
Sep 2021
CompletionActual
Sep 2021
Last update
Feb 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01927432
Lead sponsor
Cornell University
Responsible party
Sponsor
First posted
Aug 22, 2013
Start date
Sep 2011
Primary completion
Sep 2021
Completion
Sep 2021
Last update
Feb 9, 2024

Study contacts

Marla E. Lujan, PhD
principal investigator · Cornell University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion